Successful Treatment of a Patient with Brentuximab Vedotin-Refractory ALK-Negative Anaplastic Large Cell Lymphoma with Romidepsin

Successful Treatment of a Patient with Brentuximab Vedotin-Refractory ALK-Negative Anaplastic Large Cell Lymphoma with Romidepsin

We present the case of a 78-year-old male patient who was diagnosed with anaplastic lymphoma kinase (ALK)-negative, CC chemokine receptor 4 (CCR4)-negative, and CD30-positive anaplastic large cell lymphoma (ALCL). The patient had a past medical history of adult T-cell leukemia/lymphoma and colon can...

Full description

Bibliographic Details
Main Authors: Tatsuro Jo, Takahiro Sakai, Kaori Matsuzaka, Haruna Shioya, Hiroo Tominaga, Yohei Kaneko, Shizuka Hayashi, Masatoshi Matsuo, Jun Taguchi, Kuniko Abe, Kazuto Shigematsu
Format: Article
Language:English
Published: Karger Publishers 2020-11-01
Series:Case Reports in Oncology
Subjects:
adult t-cell leukemia/lymphoma
anaplastic large cell lymphoma
colon cancer
cytotoxic t lymphocyte
human t-lymphotropic virus type 1 tax
romidepsin
Online Access:https://www.karger.com/Article/FullText/511111

Internet

https://www.karger.com/Article/FullText/511111

Similar Items